Receptor News and Research

RSS

Could cow's milk provide some passive immunity against COVID-19?

Researchers at the Department of Animal Health, University of Cordoba, Córdoba, Spain, speculate that bovine milk consumption – specifically from cows with resistance to bovine coronaviruses – may potentially provide at least some degree of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The article is available to read in full on the Frontiers in Immunology website.

13 Apr 2021

New fluorescent probe can differentiate between B and T lymphocytes

Human blood contains several different components, including plasma, red blood cells (RBCs), white blood cells (WBCs), and platelets. Among these, WBCs are divided into numerous subcategories each with unique functions and characteristics, such as lymphocytes, monocytes, neutrophils, and others.

13 Apr 2021

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

In a recent bioRxiv* preprint, the large team of researchers evaluated a SARS-CoV-2 Spike receptor-binding domain ferritin nanoparticle protein vaccine (RFN) in a nonhuman primate challenge model. This study addresses the need for a next-generation, efficacious vaccine with an increased pan-SARS breadth of coverage.

13 Apr 2021

ACE2 homology in laboratory and wild animals

A new preprint research paper posted to the bioRxiv server describes the conservation of an important receptor gene for the virus among several animal species that live in close contact or proximity to humans.

13 Apr 2021

Zipper motif mediates SARS-CoV-2 spike trimerization within host cell membrane

A new preprint research paper posted to the bioRxiv* server describes the results of a nuclear magnetic resonance (NMR) study to determine the structure of the S protein transmembrane domain (TMD) and its membrane-proximal regions.

13 Apr 2021

Psychedelic drugs may work in multiple ways in the brain

University of Maryland School of Medicine (UMSOM) researchers have shown that psilocybin—the active chemical in “magic mushrooms”— still works its antidepressant-like actions, at least in mice, even when the psychedelic experience is blocked.

13 Apr 2021

Nanobody cocktails neutralize SARS-CoV-2 and variants

Researchers report a collection of nanobodies derived from llamas, some of which can work synergistically and work against newer virus variants.

12 Apr 2021

Researchers uncover a new source of energy expending brown fat cells

A new source of energy expending brown fat cells has been uncovered by researchers at the Joslin Diabetes Center, which they say points towards potential new therapeutic options for obesity.

12 Apr 2021

Research could lead to better treatment for aggressive prostate cancer

New research from CU Cancer Center member Scott Cramer, PhD, and his colleagues could help in the treatment of men with certain aggressive types of prostate cancer.

12 Apr 2021

Exercise training may slow breast cancer growth by increasing anti-tumor immune response

Exercise training may slow tumor growth and improve outcomes for females with breast cancer - especially those treated with immunotherapy drugs - by stimulating naturally occurring immune mechanisms, researchers at Massachusetts General Hospital and Harvard Medical School have found.

12 Apr 2021

Early cardiac events pose major and different risks in close relatives, finds study

Family history of early cardiac events in first degree relatives such as a parent or sibling is a major risk factor, especially for premature events. Currently, data on risks in close relatives of patients with a family history of premature heart attacks, chronic stable angina or peripheral vascular disease are sparse.

12 Apr 2021

Research may lead to a significant breakthrough in the battle against deadly brain tumors

Groundbreaking research from Tel Aviv University may lead to a significant breakthrough in the battle against deadly brain cancer.

12 Apr 2021

Breast cancer survivors with excess body weight at increased risk of developing second cancer

Breast cancer survivors who are overweight have a statistically significant increased risk of developing second primary cancers, according to results from a study conducted by Kaiser Permanente researchers and published in the Journal of the National Cancer Institute.

12 Apr 2021

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

A new study addresses an urgent need – namely, a therapeutic antibody directed specifically against a key SARS-CoV-2 antigen which is highly conserved among similar viruses, and is not easily bypassed by viral escape mutations.

12 Apr 2021

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.

12 Apr 2021

Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells

A team of scientists from the United Kingdom recently investigated the ultrastructural details of the attachment, entry, and budding processes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the human airway epithelium. They have used a highly differentiated air-liquid interface cultures of airway epithelium to thoroughly investigate the viral infection cycle. The study is currently available on the bioRxiv* preprint server.

12 Apr 2021

Researchers explore an inhalable SARS-CoV-2 nanobody therapy

Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. They reported Nb phage display libraries derived from four camels immunized with the SARS-CoV-2 spike RBD.

12 Apr 2021

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Researchers at the Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, USA, showed that the SARS-CoV-2 spike E484K mutation reduces antibody neutralization.

12 Apr 2021

Researchers work to develop dual antigen COVID-19 vaccine candidate

A new study has been published on the medRxiv* preprint server, which focuses on the development of a dual-antigen COVID-19' T cell' vaccine. This vaccine is developed based on the expression of both S protein and nucleocapsid (N) protein of SARS-CoV-2, using a next-generation human adenovirus serotype 5 (Ad5) platform.

12 Apr 2021

Could N protein-based COVID-19 vaccines hinder SARS-CoV-2's NK cell inhibition?

Upon SARS-CoV-2 infection, what are the changes occurring on the surface of the host cell? To address this, and a team of researchers undertook a study exploring the natural killer (NK) cells and their role during a SARS-CoV-2 infection.

12 Apr 2021